Phase 1, Cohort 2

The name 'Phase 1, Cohort 2' refers to a specific study group within a clinical trial rather than a distinct pharmaceutical agent. In the provided context, this designation is associated with the evaluation of **edicotinib** (also known as JNJ-40346527), an orally available small molecule inhibitor of the colony-stimulating factor-1 receptor (CSF1R; also called FMS). Developed by Janssen Research & Development (a Johnson & Johnson company), edicotinib works by blocking the interaction between the FMS receptor and its ligand CSF1, thereby inhibiting signaling pathways that drive cell proliferation in certain cancers and inflammatory conditions. It has been investigated in a Phase 1/2 dose-escalation study (NCT01572519) for relapsed or refractory Hodgkin lymphoma, as well as in trials for rheumatoid arthritis, Crohn's disease, prostate cancer, acute myeloid leukemia, and Alzheimer's disease. As of now, edicotinib has not received regulatory approval for any indication.

Other names

Phase 1, Cohort 2edicotinib